CD44 variant isoform v10 is expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-independent heterotypic cell-cell adhesion to melanoma cells

Experimental Dermatology

Volumn 12, Issue 2, 2003, Pages 204-212

  Weimann, T K ^a   Wagner, C ^a   Goos, M ^a   Wagner, Stephan N ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Adhesion; CD44; Melanoma; Regression; Tumor infiltrating lymphocytes

Indexed keywords

CD44V ANTIGEN; CD44V10 ANTIGEN; COLLAGEN; HERMES ANTIGEN; HYALURONIC ACID; INTEGRIN; SELECTIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CANCER REGRESSION; CELL ADHESION; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALIGNANT TRANSFORMATION; MELANOMA CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTIGENS, CD44; CELL ADHESION; CELL LINE, TUMOR; COLLAGEN; HUMANS; HYALURONIC ACID; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM REGRESSION, SPONTANEOUS; PROTEIN ISOFORMS; SKIN NEOPLASMS; VARIATION (GENETICS);

EID: 0042674082     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0625.2003.00044.x     Document Type: Article

References (60)

1. McGovern V J. Spontaneous regression in melanoma. Pathology 1975: 7: 91.
2. Fenton R G, Longo D L. Danger versus tolerance. Paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J Natl Cancer Inst 1997: 89: 272-275.
3. Poppema S, Brocker E B, De Leij L et al. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 1983: 51: 77-82.
4. Strohal R, Marberger K, Pehamberger H, Stingl G. Immunohistological analysis of anti-melanoma host responses. Arch Dermatol Res 1994: 287: 28-35.
5. Mackensen A, Carcelain G, Viel S et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 1994: 93: 1397-1402.
6. Thor Straten P, Becker J C, Seremet T, Bröcker E B, Zeuthen J. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 1996: 98: 279-284.
7. Stepp S E, Mathew P A, Bennett M, De Saint Basile G, Kumar V. Perforin: More than just an effector molecule. Immunol Today 2000: 21: 254-256.
8. Orlinick J R, Vaishnaw A K, Elkon K B. Structure and function of Fas/Fas ligand. Int Rev Immunol 1999: 18: 293-308.
9. Rosenberg S A, Yannelli J R, Yang J C et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994: 86: 1159-1166.
10. Marincola F M, Ettinghausen S, Cohen P A et al. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J Immunol 1994: 152: 3500-3513.
11. Cameron R B, Spiess P J, Rosenberg S A. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2, and local irradiation. Studies on the mechanism of action. J Exp Med 1990: 171: 249-263.
12. Butcher E C, Picker L J. Lymphocyte homing and homeostasis. Science 1996: 272: 60-66.
13. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu Rev Immunol 1994: 12: 735-773.
14. Norris D A. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 1990: 95 (Suppl. 6): 111S-120S.
15. Gahmberg C G, Valmu L, Fagerholm S et al. Leukocyte integrins and inflammation. Cell Mol Life Sci 1998: 54: 549-555.
16. DeGrendele H C, Kosfiszer M, Estess P, Siegelman M H. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 1997: 159: 2549-2553.
17. DeGrendele H C, Estess P, Siegelman M H. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997: 278: 672-675.
18. DeGrendele H C, Estess P, Picker L J, Siegelman M H. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996: 183: 1119-1130.
19. Wahbi A, Marcusson J A, Sundqvist K G. Expression of adhesion molecules and their ligands in contact allergy. Exp Dermatol 1996: 5: 12-19.
20. Camp R L, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med 1993: 178: 497-507.
21. Shimizu Y, Van Seventer G A, Siraganian R, Wahl L, Shaw S. Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol 1989: 143: 2457-2463.
22. Galandrini R, Galluzzo E, Albi N, Grossi C E, Velardi A. Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. J Immunol 1994: 153: 21-31.
23. Matsumoto G, Nghiem M P, Nozaki N, Schmits R, Penninger J M. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity. J Immunol 1998: 160: 5781-5789.
24. Brown T A, Bouchard T, St. John T, Wayner E, Carter W G. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991: 113: 207-221.
25. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992: 116: 817-825.
26. Screaton G R, Bell M V, Jackson D G, Cornelis F B, Gerth U, Bell J I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992: 89: 12160-12164.
27. Lesley J, Hyman R, Kincade P W. CD44 and its interaction with extracellular matrix. Adv Immunol 1993: 54: 271-335.
28. Jackson D G, Bell J I, Dickinson R, Timans J, Shields J, Whittle N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995: 128: 673-685.
29. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991: 10: 343-348.
30. Günthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991: 65: 13-24.
31. Arch R, Wirth K, Hoffmann M et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44 [see comments]. Science 1992: 257: 682-685.
32. Wittig B M, Johansson B, Zöller M, Schwarzler C, Günthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 2000: 191: 2053-2064.
33. Katagiri Y U, Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell mortality and chemotaxis. Cancer Res 1999: 59: 219-226.
34. Wagner S N, Wagner C, Reinhold U, Funk R, Zöller M, Goos M. Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes. J Invest Dermatol 1998: 111: 464-471.
35. Weimann T K, Wagner C, Funk R et al. Hyaluronan-independent adhesion of CD44H+ and CD44v10 lymphocytes to dermal microvascular endothelial cells and keratinocytes. J Invest Dermatol 2001: 117: 949-957.
36. Wagner S N, Schultewolter T, Wagner C et al. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression. Laboratory Invest 1998: 78: 541-550.
37. Stamper H B Jr, Woodruff J J. Lymphocyte homing into lymph nodes: In vitro demonstration of the selective affinity of recirculating lyphocytes for high-endothelial venules. J Exp Med 1976: 144: 828-833.
38. Salmi M, Grenman R, Grenman S, Nordman E, Jalkanen keratinocyte S. Tumor endothelium selectively supports binding of IL-2-propagated tumor-infiltrating lymphocytes. J Immunol 1995: 154: 6002-6012.
39. Hallmann R, Jutila M A, Smith C W, Anderson D C, Kishimoto T K, Butcher E C. The peripheral lymph node homing receptor, LECAM-1, is involved in CD18-independent adhesion of human neutrophils to endothelium. Biochem Biophys Res Commun 1991: 174: 236-243.
40. Behrens J, Mareel M M, Van Roy F M, Birchmeier W. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989: 108: 2435-2447.
41. Butcher E C. Leukocyte-endothelial cell recognition: Three (ore more) steps to specifity and diversity. Cell 1991: 67: 1033-1036.
42. Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994: 76: 301-314.
43. Uksila J, Salmi M, Butcher E C, Tarkkanen J, Jalkanen S. Function of lymphocyte homing-associated adhesion molecules on human natural killer and lymphokine-activated killer cells. J Immunol 1997: 158: 1610-1617.
44. Nandi A, Estess P, Siegelman M H. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000: 275: 14939-14948.
45. Siegelman M H, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest 2000: 105: 683-691.
46. Bruynzeel I, Koopman G, Van Der Raaij L M, Pals S T, Willemze R. CD44 antibody stimulates adhesion of peripheral blood T cells to keratinocytes through the leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Invest Dermatol 1993: 100: 424-428.
47. Butcher E C, Weissman I L In: Paul W E, ed. Fundamental Immunology. New York: Raven Press, 1989.
48. Aruffo A, Stamenkovic I, Melnick M, Underhill C B, Seed B. CD44 is the principle cell surface receptor for hyaluronate. Cell 1990: 61: 1303-1313.
49. Luke H J, Prehm P. Synthesis and shedding of hyaluronan from plasma membranes of human fibroblasts and metastatic and non-metastatic melanoma cells. Biochem J 1999: 343 Part 1: 71-75.
50. Sy M S, Guo Y J, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991: 174: 859-866.
51. Naot D, Sionov R V, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997: 71: 241-319.
52. Koopman G, Van Kooyk Y, De Graaff M, Meyer C J, Figdor C G, Pals S T. Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990: 145: 3589-3593.
53. Fujisaki T, Tanaka Y, Fujii K et al. CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res 1999: 59: 4427-4434.
54. Fujii K, Tanaka Y, Hubscher S, Saito K, Ota T, Eto S. Cross-linking of CD44 on rheumatoid synovial cells up-regulates VCAM-1. J Immunol 1999: 162: 2391-2398.
55. Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 1996: 135: 1139-1150.
56. Rosenberg L C, Choi H U, Tang L H et al. Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem 1985: 260: 6304-6313.
57. Yamagata M, Suzuki S, Akiyama SK, Yamada K M, Kimata K. Regulation of cell-substrate adhesion by proteoglycans immobilized on extracellular substrates. J Biol Chem 1989: 264: 8012-8018.
58. Faassen A E, Schrager J A, Klein D J, Oegema T R, Couchman J R, McCarthy J B. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992: 116: 521-531.
59. Chiu R K, Droll A, Dougherty S T, Carpenito C, Cooper D L, Dougherty G J. Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesion through the recognition of chondroitin sulfate modified CD44. Exp Cell Res 1999: 248: 314-321.
60. Herrlich P, Morrison H, Sleeman J et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 2000: 910: 106-118.